Artiva Biotherapeutics
Artiva Biotherapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$79 million. The diluted share count rose 117.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Artiva Biotherapeutics does
Artiva Biotherapeutics is a clinical-stage biotech company with no approved products. It is developing natural killer (NK) cell therapies for autoimmune diseases and cancers. NK cells are immune cells; Artiva's come from donors rather than from each patient, and are made ahead of time, frozen and shipped to the treatment site.
Its lead candidate, AlloNK, is a cell therapy meant to work with antibody drugs to clear B cells, the immune cells that drive many autoimmune diseases. It is being tested in patients with rheumatoid arthritis and other autoimmune diseases, and it has received FDA Fast Track designation in refractory rheumatoid arthritis. Artiva is prioritizing refractory rheumatoid arthritis as its lead use.
Artiva also has CAR-NK candidates tested in trials that partners fund, and it holds rights to its programs outside the Asia-Pacific region. Its Affimed collaboration ended in July 2025 after Affimed filed for insolvency. The company has not yet sold a product.
Its biggest risks, as it describes them
- Having no products approved for sale and a limited operating history.
- Needing substantial additional funding, which may dilute shareholders.
- Dependence on AlloNK, whose approach to treating autoimmune disease with NK cells is unproven.
- Clinical trials that are costly, may be delayed and may show serious side effects.
- Trade policies, tariffs and trade barriers.
Income statement
Artiva Biotherapeutics lost money in fiscal 2025: a net loss of $84 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 77 | 185 | 108 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 6.5x | 15.4x | 8.6x |
| Quick ratio | 6.5x | 15.4x | 8.6x |
Cash flow
Projections
Project Artiva Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 7 insiders bought $109.1 million of Artiva Biotherapeutics shares on the open market, and 6 insiders sold $2.4 million, $378,861 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Fred AslanChief Executive Officer, Director | Sold | 119,771 | $3.91 | $468,532 | Form 4 |
| Nov 17, 2026 | Christopher HoranChief Tech Operations Officer | Sold | 20,546 | $3.91 | $80,374 | Form 4 |
| Nov 17, 2026 | Jennifer BushCOO, CLO, Compliance Officer | Sold | 19,217 | $3.91 | $75,175 | Form 4 |
| Nov 17, 2026 | Subhashis BanerjeeChief Medical Officer | Sold | 4,037 | $3.91 | $15,792 | Form 4 |
| Nov 17, 2026 | Gines Diego MirallesPresident & Head of R&D | Sold | 1,043 | $3.91 | $4,080 | Form 4 |
| Sep 8, 2026 | Fred AslanChief Executive Officer, Director | Sold plan | 23,429 | $10.92 | $255,845 | Form 4 |
| Sep 3, 2026 | Fred AslanChief Executive Officer, Director | Sold | 61,888 | $11.16 | $690,670 | Form 4 |
| Sep 3, 2026 | Christopher HoranChief Tech Operations Officer | Sold | 10,366 | $11.16 | $115,685 | Form 4 |
| Sep 3, 2026 | Jennifer BushCOO, CLO, Compliance Officer | Sold | 8,391 | $11.16 | $93,644 | Form 4 |
| Sep 3, 2026 | Subhashis BanerjeeChief Medical Officer | Sold | 1,100 | $11.16 | $12,276 | Form 4 |
| Aug 27, 2026 | Subhashis BanerjeeChief Medical Officer | Sold plan | 8,222 | $12.01 | $98,746 | Form 4 |
| Aug 18, 2026 | Subhashis BanerjeeChief Medical Officer | Sold plan | 429 | $12.00 | $5,148 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −22,280.1% | — |
| Altman Z'' | 8.07 | −2.34 |
| Accruals ratio | −6.6% | −4.2% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Artiva Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics | FY25 | −100.0% | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 34 | 0 | 0 |
| Revenue growth | — | −99.2% | −100.0% |
| Gross profit | — | — | — |
| Research and development | 50 | 50 | 70 |
| Operating income | −31 | −67 | −90 |
| Net income | −29 | −65 | −84 |
| Diluted EPS (US$) | −35.78 | −5.81 | −3.43 |
| Diluted shares (millions) | 1 | 11 | 24 |
| Cash flow | |||
| Cash from operations | −47 | −55 | −77 |
| Capital expenditure | 3 | 1 | 3 |
| Free cash flow | −51 | −56 | −79 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 7 | 7 | 7 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 77 | 185 | 108 |
| Debt incl. finance leases | — | — | — |
| Total assets | 105 | 210 | 131 |
| Total liabilities | 51 | 23 | 21 |
| Shareholders' equity | −162 | 187 | 110 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −91.6% | −26,805.6% | — |
| Net margin | −85.8% | −26,045.0% | — |
| Free cash flow margin | −151.3% | −22,180.9% | — |
| Rule of 40 (growth + FCF margin) | — | −22,280.1% | — |
| Return on capital | — | — | — |
| Return on equity | — | −530.9% | −56.5% |
| Return on assets | — | −41.5% | −49.3% |
| Net debt to EBITDA | — | — | — |